Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IDEAYA Biosciences (IDYA) EBITDA (2019 - 2025)

IDEAYA Biosciences (IDYA) has disclosed EBITDA for 7 consecutive years, with -$83.1 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 37.71% to -$83.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$112.2 million through Dec 2025, up 59.07% year-over-year, with the annual reading at -$112.2 million for FY2025, 59.07% up from the prior year.
  • EBITDA hit -$83.1 million in Q4 2025 for IDEAYA Biosciences, down from $119.8 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $119.8 million in Q3 2025 to a low of -$133.3 million in Q4 2024.
  • Historically, EBITDA has averaged -$30.4 million across 5 years, with a median of -$25.0 million in 2022.
  • Biggest five-year swings in EBITDA: tumbled 2274.8% in 2023 and later soared 357.2% in 2025.
  • Year by year, EBITDA stood at -$18.9 million in 2021, then fell by 22.23% to -$23.1 million in 2022, then tumbled by 41.5% to -$32.6 million in 2023, then crashed by 308.47% to -$133.3 million in 2024, then skyrocketed by 37.71% to -$83.1 million in 2025.
  • Business Quant data shows EBITDA for IDYA at -$83.1 million in Q4 2025, $119.8 million in Q3 2025, and -$77.6 million in Q2 2025.